Rewarding effects and reinstatement of MDMA-induced CPP in adolescent mice

Neuropsychopharmacology

Volumn 32, Issue 8, 2007, Pages 1750-1759

  Daza Losada, Manuel ^a   Ribeiro Do Couto, Bruno ^a   Manzanedo, Carmen ^b   Aguilar, Maria A ^a   Rodríguez Arias, Marta ^a   Mĩarro, Jose ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Conditioned place preference; Dopamine; MDMA; Mice; Reinstatement; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE; MONOAMINE; SEROTONIN; SODIUM CHLORIDE;

ADOLESCENT; ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; CONDITIONING; CONTROLLED STUDY; CORPUS STRIATUM; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REINFORCEMENT; REWARD; TRAINING;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BIOGENIC AMINES; BRAIN CHEMISTRY; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTINCTION, PSYCHOLOGICAL; HALLUCINOGENS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; REINFORCEMENT SCHEDULE; REWARD;

EID: 34447520652     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301309     Document Type: Article

References (60)

1. Acquas E, Marrocu P, Pisanu A, Cadoni C, Zernig G, Saria A et al (2001). Intravenous administration of ecstasy (3,4- methylenedioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo. Eur J Pharmacol 418: 207-211.
2. Beardsley PM, Balster RL, Harris LS (1986). Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend 18: 149-157.
3. Bilsky EJ, Reid LD (1991). MDL72222, a serotonin 5-HT3 receptor antagonist, blocks MDMA's ability to establish a conditioned place preference. Pharmacol Biochem Behav 39: 509-512.
4. Bilsky EJ, Hui Y, Hubbell CL, Reid LD (1990). Methylenedioxymethamphetamine's capacity to establish place preferences and modify intake of an alcoholic beverage. Pharmacol Biochem Behav 37: 633-638.
5. Bilsky EJ, Hubell CL, Delconte JD, Reid LD (1991). MDMA produces a conditioned place preference and elicits ejaculation in male rats: a modulatory role for the endogenous opioids. Pharmacol Biochem Behav 40: 443-447.
6. Bilsky EJ, Montegut MJ, Nichols ML, Reid LD (1998). CGS 10746B, a novel dopamine release inhibitor, blocks the establishment of cocaine and MDMA conditioned place preferences. Pharmacol Biochem Behav 59: 215-220.
7. Boot BP, Mechan AO, McCann UD, Ricaurte GA (2002). MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities. Eur J Pharmacol 453: 239-244.
8. Braida D, Sala M (2002). Role of the endocannabinoid system in MDMA intracerebral self-administration in rats. Br J Pharmacol 136: 1089-1092.
9. Braida D, Iosuè S, Pegorini S, Sala M (2005). 3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by the endocannabinoid system. Pharmacol Res 51: 177-182.
10. Cadoni C, Solinas M, Pisanu A, Zernig G, Acquas E, Di Chiara G (2005). Effects of 3,4-methylendioxymethamphetamine (MDMA, 'ecstasy') on dopamine transmission in the nucleus accumbens shell and core. Brain Res 1055: 143-148.
11. Camarero J, Sanchez V, O'Shea E, Green AR, Colado MI (2002). Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum. J Neurochem 81: 961-972.
12. Carroll ME, Comer SD (1996). Animal models of relapse. Exp Clin Psychopharmacol 4: 11-18.
13. Colado MI, Camarero J, Mechan AO, Sanchez V, Esteban B, Elliott JM et al (2001). A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurons in mouse brain. Br J Pharmacol 134: 1711-1723.
14. Colado MI, O'Shea E, Green AR (2004). Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology 173: 249-263.
15. Cole JC, Sumnall HR (2003). The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 27: 199-217.
16. Cole JC, Sumnall HR, O'Shea E, Marsden CA (2003). Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse. Psychopharmacology 166: 383-390.
17. Cornish JL, Shahnawaz Z, Thompson MR, Wong S, Morley KC, Hunt GE et al (2003). Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur J Pharmacol 482: 339-341.
18. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, ÓBrien CP (1999). Limbic activation during cue-induced cocaine craving. Am J Psychiatry 156: 11-18.
19. Daniela E, Brennan K, Gittings D, Hely L, Schenk S (2004). Effect of SCH 23390 on (+/-)-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol Biochem Behav 77: 745-750.
20. Escobedo I, O'Shea E, Orio L, Sanchez V, Segura M, de la Torre R et al (2005). A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. Br J Pharmacol 144: 231-241.
21. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G (2002). 3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology 161: 356-364.
22. Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G et al (2004). Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 29: 1270-1281.
23. Gough B, Ali SF, Slikker W, Holson RR (1991). Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 39: 619-623.
24. Grimm JW, Hope BT, Wise RA, Shaham Y (2001). Incubation of cocaine craving after withdrawal. Nature 412: 141-142.
25. Herzig V, Capuani EM, Kovar KA, Schmidt WJ (2005). Effects of MPEP on expression of food-, MDMA- or amphetamine-conditioned place preference in rats. Addict Biol 10: 243-249.
26. Hiramatsu M, Cho AK (1990). Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Neuropharmacology 29: 269-275.
27. Kankaanpaa A, Meririnne E, Lillsunde P, Seppala T (1998). The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol Biochem Behav 59: 1003-1009.
28. Koch S, Galloway MP (1997). MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104: 135-146.
29. Lamb R, Griffiths R (1987). Self-injections of d-3,4- methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology 91: 268-272.
30. Li S-M, Ren Y-H, Zheng J-W (2002). Effect of 7-nitroindazole on drug-priming reinstatement of D-methamphetamine-induced conditioned place preference. Eur J Pharmacol 443: 205-206.
31. Lile JA, Ross JT, Nader MA (2005). A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') with cocaine in rhesus monkeys. Drug Alcohol Depend 78: 135-140.
32. Lu L, Grimm JW, Dempsey J, Shaham Y (2004). Cocaine seeking over extended withdrawal periods in rats: different time courses of responding induced by cocaine cues versus cocaine priming over the first 6 months. Psychopharmacology 176: 101-108.
33. Maldonado C, Rodriguez-Arias M, Castillo A, Aguilar MA, Miñarro J (2006). Gamma-hydroxybutyric acid affects the acquisition and reinstatement of cocaine-induced conditioned place preference in mice. Behav Pharmacol 17: 119-131.
34. Manzanedo C, Aguilar MA, Rodríguez-Arias M, Miñarro J (2001). Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice. Behav Brain Res 121: 189-197.
35. Marona-Lewicka D, Rhee G-S, Sprague JE, Nichols DE (1996). Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol Biochem Behav 53: 99-105.
36. McGregor IS, Clemens KJ, van der Plass G, Li KM, Hunt GE, Chen F et al (2003). Increased anxiety 3 months after brief exposure to MDMA ('ecstasy') in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 28: 1472-1484.
37. Meyer A, Mayerhofer A, Kovar K-A, Schmidt WJ (2002). Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine ('Ecstasy') and 3,4-methylenedioxyethylamphetamine ('Eve') measured by conditioned place preference in rats. Neurosci Lett 330: 280-284.
38. Modi GM, Yang PB, Swann AC, Dafny N (2006). Chronic exposure to MDMA (Ecstasy) elicits behavioral sensitization in rats but fails to induce cross-sensitization to other psychostimulants. Behav Brain Funct 2: 1.
39. Nair SG, Gudelsky GA (2006). 3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat. Psychopharmacology 184: 182-189.
40. Nichols DE (1986). Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18: 305-313.
41. O'Brien CP (1997). A range of research-based pharmacotherapies for addiction. Science 278: 66-70.
42. O'Shea E, Escobedo J, Orio L, Sanchez V, Navarro M, Green AR et al (2005). Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats. Neuropsychopharmacology 30: 1312-1323.
43. Reveron ME, Monks TJ, Duvauchelle CL (2005). Age-dependent (+)MDMA-mediated neurotoxicity in mice. Neurotoxicology 26: 1031-1040.
44. Ribeiro Do Couto B, Aguilar MA, Rodriguez-Arias M, Miñarro J (2005a). Long-lasting rewarding effects of morphine induced by drug primings. Brain Res 1050: 53-63.
45. Ribeiro Do Couto B, Aguilar MA, Manzanedo C, Rodriguez-Arias M, Miñarro J (2005b). NMDA glutamate but not dopamine antagonists blocks drug-induced reinstatement of morphine place preference. Brain Res Bull 64: 493-503.
46. Ribeiro Do Couto B, Aguilar MA, Manzanedo C, Rodriguez-Arias M, Armario A, Miñarro J (2006). Social stress is as effective as physical stress in reinstating morphine-induced place preference in mice. Psychopharmacology 185: 459-470.
47. Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C (1985). Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229: 986-988.
48. Robledo P, Balerio B, Berrendero F, Maldonado R (2004a). Study of the behavioural responses related to the potential addictive properties of MDMA in mice. Naunyn-Schmiedeberg's Arch Pharmacol 369: 338-349.
49. Robledo P, Mendizabal V, Ortuño J, de la Torre R, Kieffer BL, Maldonado R (2004b). The rewarding properties of MDMA are preserved in mice lacking m-opioid receptors. Eur J Neurosci 20: 853-858.
50. Salzmann J, Marie-claire C, Le Guen S, Roques BP, Noble F (2003). Importance of ERK activation in behavioral and biochemical effects induced by MDMA in mice. Br J Pharmacol 140: 831-838.
51. Schechter MD (1991). Effect of MDMA neurotoxicity upon its conditioned place preference and discrimination. Pharmacol Biochem Behav 38: 539-544.
52. Schenk S, Gittings D, Johnstone M, Daniela E (2003). Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology 169: 21-27.
53. Schmidt CJ, Levin JA, Lovenberg W (1987). In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 36: 747-755.
54. Shaham Y, Shalev U, Lu L, de Wit H, Stewart J (2003). The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 168: 3-20.
55. Shalev U, Grimm JW, Shaham Y (2002). Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 54: 1-42.
56. Stone DM, Johnson M, Hanson GR, Gibb JW (1987). A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur J Pharmacol 134: 245-248.
57. Trigo JM, Panayi F, Soria G, Maldonado R, Robledo P (2006). A reliable model of intravenous MDMA self-administration in naive mice. Psychopharmacology 184: 212-220.
58. Weiss F (2005). Neurobiology of craving, conditioned reward and relapse. Current Opinion Pharmacol 5: 9-19.
59. White SR, Duffy P, Kalivas PW (1994). Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo. Neuroscience 62: 41-50.
60. Yamamoto BK, Spanos LJ (1988). The acute effects of methylenedioxy- methamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 148: 195-203.